<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885155</url>
  </required_header>
  <id_info>
    <org_study_id>2006CPRC/CHABOT</org_study_id>
    <nct_id>NCT02885155</nct_id>
  </id_info>
  <brief_title>Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension</brief_title>
  <official_title>Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the prognostic value of echocardiographic&#xD;
      parameters in comparison with clinical and hemodynamic parameters in pulmonary arterial&#xD;
      hypertension (PAH).&#xD;
&#xD;
      A secondary purpose of this study is to analyze the disease evolution after 3 to 6 months. In&#xD;
      pulmonary fibrosis it has been demonstrated that the variation of clinical and paraclinical&#xD;
      parameters between 2 examinations has a prognostic interest. In this study the prognostic&#xD;
      value of variation of some echocardiographic parameters between initial examination and&#xD;
      echocardiography after 3 or 6 months will be evaluated.&#xD;
&#xD;
      Another secondary purpose is to create a common database for Pneumology, Cardiology and&#xD;
      Epidemiology departments with prospective registration of new cases of PAH and follow of&#xD;
      patients under treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is a rare pathology with a poor prognosis and a median&#xD;
      survival lower than 3 years in the absence of a specific treatment.&#xD;
&#xD;
      The prognostic evaluation is based on clinical and hemodynamic data needing the right cardiac&#xD;
      catheterization. It has been shown that prognosis depends essentially on the severity of&#xD;
      right ventricular dysfunction. Recently, various echocardiographic parameters derived from&#xD;
      new techniques such as tissue Doppler have been validated for the evaluation of right&#xD;
      ventricular function. Some have been used as prognostic factor in cardiac insufficiency, but&#xD;
      not in PAH.&#xD;
&#xD;
      This is an observational retrospective and then prospective study. Usual PAH assessment&#xD;
      includes a complete clinical and paraclinical evaluation. History and physical examination&#xD;
      assess dyspnea, search signs of disease severity and quantify functional impact of 6&#xD;
      min-walking test. An echocardiography and a right cardiac catheterization are realized in all&#xD;
      patients. Clinical consultations of patients and control echocardiographic and hemodynamic&#xD;
      examinations are programmed at regular intervals.&#xD;
&#xD;
      The demonstration of prognostic value of some echocardiographic parameters could diminish&#xD;
      right cardiac catheterizations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at 5 years</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with pulmonary arterial hypertension</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>planned at regular intervals</description>
    <arm_group_label>Patients with pulmonary arterial hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hemodynamic examinations (right cardiac catheterization)</intervention_name>
    <description>planned at regular intervals</description>
    <arm_group_label>Patients with pulmonary arterial hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary arterial hypertension followed at CHU Nancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mean pulmonary artery pressure &gt; 25 mmHg in hemodynamics&#xD;
&#xD;
          -  according to Venice classification: Idiopathic PAH or associated to other known risk&#xD;
             factors (anorectics, portal hypertension, connective tissue diseases, in particular&#xD;
             scleroderma but also lupus, congenital heart disease with Eisenmenger syndrome, HIV&#xD;
             infection)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Poor echogenicity&#xD;
&#xD;
          -  PAH associated to another factor, thromboembolic disease, respiratory insufficiency,&#xD;
             left heart disease or mitral or aortic valvulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Chabot, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Maladies Respiratoires et Réanimation Respiratoire - CHU Nancy</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

